NASDAQ:AMRN - Amarin Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$17.66 +0.31 (+1.79 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$17.35
Today's Range$17.31 - $17.7550
52-Week Range$2.35 - $23.33
Volume3.98 million shs
Average Volume8.19 million shs
Market Capitalization$5.70 billion
P/E Ratio-70.64
Dividend YieldN/A
Beta1.16
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has collaboration with Mochida Pharmaceutical Co., Ltd. for the development of EPA-Based drug products and indications. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is headquartered in Dublin, Ireland.

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$181.10 million
Book Value($0.33) per share

Profitability

Net Income$-67,860,000.00

Miscellaneous

Employees241
Market Cap$5.70 billion
OptionableOptionable

Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) issued its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The biopharmaceutical company earned $47.10 million during the quarter, compared to the consensus estimate of $45.85 million. The business's quarterly revenue was up 45.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.08) earnings per share. View Amarin's Earnings History.

When is Amarin's next earnings date?

Amarin is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Amarin.

What guidance has Amarin issued on next quarter's earnings?

Amarin issued an update on its FY 2019 earnings guidance on Friday, January, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $350-350 million, compared to the consensus revenue estimate of $417.53 million.Amarin also updated its FY 2018 guidance to EPS.

What price target have analysts set for AMRN?

5 brokerages have issued 1-year price targets for Amarin's shares. Their forecasts range from $20.00 to $51.00. On average, they expect Amarin's share price to reach $33.20 in the next year. This suggests a possible upside of 88.0% from the stock's current price. View Analyst Price Targets for Amarin.

What is the consensus analysts' recommendation for Amarin?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (1/23/2019)
  • 2. Cantor Fitzgerald analysts commented, "We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35." (12/14/2018)
  • 3. HC Wainwright analysts commented, "We believe that beyond the topline of 25% reduction of MACE score, the robustness of the data is highlighted by the consistency across pre-specified analyses. A key secondary composite, namely 3-point MACE score (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke), which assesses the major CV events (and reflects the most important clinical relevance), showed an even higher reduction of risks at 26% compared to placebo. The clinical benefits as measured by the primary endpoint of MACE score and the key secondary 3-point MACE score are observed across subgroups (statistically significant in the vast majority of the subgroups), which speaks to the validity and robustness of the data." (11/12/2018)

Has Amarin been receiving favorable news coverage?

News coverage about AMRN stock has trended somewhat positive this week, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amarin earned a daily sentiment score of 1.1 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the stock's share price in the next several days.

Are investors shorting Amarin?

Amarin saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 15,065,645 shares, a decrease of 11.2% from the January 15th total of 16,974,105 shares. Based on an average daily volume of 7,767,156 shares, the days-to-cover ratio is currently 1.9 days. Currently, 5.2% of the shares of the company are sold short. View Amarin's Current Options Chain.

Who are some of Amarin's key competitors?

Who are Amarin's key executives?

Amarin's management team includes the folowing people:
  • Mr. John F. Thero, Pres, CEO & Director (Age 58)
  • Mr. Michael W. Kalb, CFO, Sr. VP & Assistant Sec. (Age 48)
  • Dr. Steven B. Ketchum, Pres of R&D, Sr. VP and Chief Scientific Officer (Age 54)
  • Mr. Joseph T. Kennedy, Exec. VP, Gen. Counsel & Strategic Initiatives (Age 51)
  • Ms. Elisabeth Schwartz, Sr. Director of Investor Relations

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (1.73%), Perceptive Advisors LLC (1.51%), BlackRock Inc. (1.04%), Eversept Partners LP (0.39%), Opaleye Management Inc. (0.39%) and Two Sigma Investments LP (0.38%). Company insiders that own Amarin stock include John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Institutional Ownership Trends for Amarin.

Which institutional investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Stonepine Capital Management LLC, Opaleye Management Inc., Two Sigma Advisers LP, Frontier Capital Management Co. LLC, GSA Capital Partners LLP, Bank of America Corp DE and Tekla Capital Management LLC. Company insiders that have sold Amarin company stock in the last year include John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Insider Buying and Selling for Amarin.

Which institutional investors are buying Amarin stock?

AMRN stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, venBio Select Advisor LLC, Two Sigma Investments LP, Elk Creek Partners LLC, Gladstone Capital Management LLP, Eversept Partners LP, Chartwell Investment Partners LLC and State of New Jersey Common Pension Fund D. View Insider Buying and Selling for Amarin.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $17.66.

How big of a company is Amarin?

Amarin has a market capitalization of $5.70 billion and generates $181.10 million in revenue each year. The biopharmaceutical company earns $-67,860,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Amarin employs 241 workers across the globe.

What is Amarin's official website?

The official website for Amarin is http://www.amarincorp.com.

How can I contact Amarin?

Amarin's mailing address is 2 Pembroke House Upper Pembroke Street 28-32, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]


MarketBeat Community Rating for Amarin (NASDAQ AMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  603 (Vote Outperform)
Underperform Votes:  363 (Vote Underperform)
Total Votes:  966
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/15/2019 by MarketBeat.com Staff

Featured Article: Front-End Load

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel